865 20 865 20 865 20 865 20 tablets 1 linezolid was sifted through astm 24 mesh 2 maize starch microcrystalline cellulose and disintegrant were sifted through astm 40 mesh and dry mixed with step 1 for sufficient time 3 magnesium stearate was sifted through astm 40 mesh and added into step 2 and was mixed for sufficient time 4 the blend of step 3 was used to form compacts of sufficient hardness using roller compactor 5 the compacts of step 4 were milled using multi mill screen of 2 mm and were passed through astm 16 mesh 6 microcrystalline cellulose and disintegrant were sifted through astm 40 mesh and loaded into blender of suitable size and were mixed with sized granules of step 5 7 magnesium stearate was sifted through astm 40 mesh and added to step 6 and mixed for sufficient time 8 lubricated blend of step 7 was compressed into tablets 9 compressed tablets of step 7 were coated with opadry white till weight gain of 3 was achieved the dissolution was more than 90 in 45 minutes for the tablets of example 1a containing soy polysaccharide as disintegrant with reduced gelling tendency the crystallinity of polymorph is determined by using x ray powder diffraction xrd at initial as well as stability stages fig1 overlay xrd diffractograms of the linezolid form iii pharmaceutical composition at 40 u00b0 c 75 rh fig1 depicts polymorphic content of pharmaceutical composition 1a which was determined by x ray powder diffraction for initial 1 2 3 and 6 months respectively characteristic peaks at reflection angle 2 u03b8 theta values of linezolid form iii viz 7 038 9 292 13 439 18 39 18 657 22.